[Lacosamide. A new antiepileptic drug as adjunctive therapy in patients with partial-onset seizures].
Lacosamide (Vimpat) is an aniepileptic drug with a new, dual mode of action. Lacosamide enhances slow inactivation of voltage-gated sodium channels and modulates the collapsin response mediator protein-2 (CRMP-2), a protein, which is part of neuronal signal transduction pathways and which is attributed to neuroprotection. Reduction of seizure frequency could be demonstrated in several clinical studies in patients with partial-onset seizures who received lacosamide in addition to other antiepileptic drugs.